BNP Paribas Financial Markets Sells 204,974 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

BNP Paribas Financial Markets lowered its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 78.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,351 shares of the company’s stock after selling 204,974 shares during the period. BNP Paribas Financial Markets’ holdings in Elanco Animal Health were worth $670,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in ELAN. Jones Financial Companies Lllp boosted its stake in Elanco Animal Health by 95.6% during the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock worth $51,000 after buying an additional 2,059 shares during the period. SRS Capital Advisors Inc. lifted its holdings in shares of Elanco Animal Health by 221.2% in the 4th quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company’s stock worth $60,000 after acquiring an additional 3,411 shares during the last quarter. MRP Capital Investments LLC purchased a new position in shares of Elanco Animal Health during the 4th quarter worth about $61,000. Blue Trust Inc. grew its holdings in Elanco Animal Health by 47.7% during the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company’s stock valued at $71,000 after purchasing an additional 1,894 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd raised its position in Elanco Animal Health by 3,267.6% in the 4th quarter. Harvest Fund Management Co. Ltd now owns 6,129 shares of the company’s stock worth $74,000 after purchasing an additional 5,947 shares during the period. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Price Performance

Shares of ELAN stock opened at $12.68 on Friday. Elanco Animal Health Incorporated has a twelve month low of $8.02 and a twelve month high of $18.80. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The stock has a fifty day simple moving average of $10.30 and a two-hundred day simple moving average of $11.46. The stock has a market capitalization of $6.30 billion, a price-to-earnings ratio of 31.70, a P/E/G ratio of 2.50 and a beta of 1.49.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.06. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm’s revenue for the quarter was down 1.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.34 earnings per share. On average, analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on ELAN. Morgan Stanley dropped their target price on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 26th. Stifel Nicolaus boosted their price objective on Elanco Animal Health from $15.00 to $16.00 and gave the company a “buy” rating in a report on Monday. Piper Sandler cut their price objective on Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a research report on Thursday, March 6th. UBS Group decreased their target price on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Finally, Barclays lowered their target price on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $15.17.

Insider Buying and Selling at Elanco Animal Health

In other news, Director Lawrence Erik Kurzius bought 10,000 shares of the stock in a transaction on Friday, March 7th. The stock was bought at an average cost of $10.90 per share, for a total transaction of $109,000.00. Following the completion of the purchase, the director now directly owns 101,459 shares in the company, valued at approximately $1,105,903.10. The trade was a 10.93% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.89% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.